Company Overview and News

 
AB Science annonce que le CHMP a adopté une opinion négative pour l'enregistrement du masitinib dans le traitement de la sclérose latérale amyotrophique

9h globenewswire
AB Science annonce que le CHMP a adopté une opinion négative pour l'enregistrement du masitinib dans le traitement de la sclérose latérale amyotrophique
Upvote Downvote

 
AB Science announces that the CHMP has adopted a negative opinion for the marketing authorization of masitinib in Amyotrophic Lateral Sclerosis

9h globenewswire
AB Science announces that the CHMP has adopted a negative opinion for the marketing authorization of masitinib in Amyotrophic Lateral Sclerosis
Upvote Downvote

 
3 Things In Biotech You Should Learn Today: September 17, 2017

2017-09-17 seekingalpha
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.
Upvote Downvote

2
Prostate Cancer Pipeline H1 2017 Therapeutic Key Players 3-V Biosciences Inc, 4SC AG, Actinium Pharmaceuticals Inc and Advaxis Inc, Says a New Research Report at RnRMarketResearch.com

2017-07-11 prnewswire
Prostate Cancer Pipeline Review, H1 2017 is new research report highlights details analysis includes 1845 pages with latest updates, Drug Profiles, Key players, Table of Contents, List of Tables, List of Figures.
Upvote Downvote

 
French Regulators Order AB Science to Temporarily Suspend Work on Phase III ALS Trial

2017-05-12 biospace
AB Science announces that ANSM requested the temporary suspension of clinical studies conducted in France following deviations from Good Clinical Practice (GCP) standards
Upvote Downvote

 
Mitsubishi Bags ALS Approval Without Radical Benefit

2017-05-09 seekingalpha
Amyotrophic lateral sclerosis (ALS) patients will no doubt be relieved to have a new option after the FDA approved Mitsubishi Tanabe Pharma's edaravone, known in the US as Radicava. But with a $145,000-per-year price tag and no proof yet that it improves survival, getting it paid for might be a different matter.
Upvote Downvote

 
Pipeline of Depression Market Covering Therapeutics Under Development for H2 2016

2016-10-24 prnewswire
RnRMarketResearch.com adds "Depression - Pipeline Review, H2 2016" to its store. The report provides an overview of the Depression's therapeutic pipeline with comprehensive information on the therapeutic development for Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
Upvote Downvote

 
Collaborative Leukemia Trial Orbits Moonshot Initiative

2016-10-20 seekingalpha
The once-neglected blood cancer acute myeloid leukemia has seen a flurry of activity of late – which might explain why four companies with mid-stage projects are taking the unusual step of getting involved in a collaborative study.
Upvote Downvote

 
Alzheimer's Disease: Market Opportunity And Major Phase 3 Treatments To Know About

2016-10-14 seekingalpha
Lilly’s (LLY) hotly anticipated Phase III data for Alzheimer’s Disease drug solanezumab has left many investors with questions about LLY and AD treatment in general.
Upvote Downvote

 
NewLink's Pancreatic Cancer Candidate Fails To Impress

2016-09-20 seekingalpha
The phase III failure of NewLink Genetics' (NASDAQ:NLNK) algenpantucel-L is not only a blow to the company, it also dashes hopes of getting a new pancreatic cancer therapy approved any time soon. Of the four pivotal trials in the disease that were due to read out this year, three have already fizzled out (see tables below).
Upvote Downvote

 
MediciNova: CEO Faces Undisclosed Illegal Kickback Lawsuit, Failed Science, Perplexing Related Party Transactions, -84% Downside

2016-09-19 seekingalpha
Perplexing illegal kickback lawsuit creates the possibility of government funding loss and cash clawback at MNOV; stock could go to zero.
Upvote Downvote

 
Colorectal Cancer Pipeline 2016 Global Market Review Covering 227 Companies

2016-08-10 prnewswire
RnRMarketResearch.com adds "Colorectal Cancer - Pipeline Review, H1 2016" market research report to its store providing an overview and comprehensive information on the therapeutic development for Colorectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
Upvote Downvote

 
Pancreatic Cancer Pipeline 2016 Market Report of 282 Companies

2016-08-02 prnewswire
ReportnReports.com adds "Pancreatic Cancer - Pipeline Review, H1 2016" market research report providing comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Cancer and special features on late-stage and discontinued projects.
Upvote Downvote

 
Pipeline of Asthma Market Covering 129 Companies Reviewed for H1 2016 in New Research Report

2016-05-31 prnewswire
RnRMarketResearch.com adds "Asthma - Pipeline Review, H1 2016" market research report with comparative analysis of Asthma therapy at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Asthma and special features on late-stage and discontinued projects.
Upvote Downvote

 
AB Science Claims A Positive Result In Masitinib ALS Study

2016-04-19 seekingalpha
France’s AB Science (OTCPK:ABSCF) seems to have notched up an unexpected positive interim readout in a phase III study with its c-KIT inhibitor, masitinib, in the difficult indication of amyotrophic lateral sclerosis (ALS). The result could represent the first progress in the ALS field in more than two decades.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...